- Home
- COCH vs LPCN Comparison
COCH vs LPCN Comparison
Compare COCH & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COCH
- LPCN
- Stock Information
- Founded
- COCH 1995
- LPCN 1997
- Country
- COCH United States
- LPCN United States
- Employees
- COCH N/A
- LPCN N/A
- Industry
- COCH Blank Checks
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- COCH Finance
- LPCN Health Care
- Exchange
- COCH Nasdaq
- LPCN Nasdaq
- Market Cap
- COCH 29.8M
- LPCN 27.1M
- IPO Year
- COCH N/A
- LPCN N/A
- Fundamental
- Price
- COCH $1.41
- LPCN $4.37
- Analyst Decision
- COCH Strong Buy
- LPCN Strong Buy
- Analyst Count
- COCH 3
- LPCN 1
- Target Price
- COCH $8.00
- LPCN $10.00
- AVG Volume (30 Days)
- COCH 54.8K
- LPCN 34.0K
- Earning Date
- COCH 11-14-2024
- LPCN 03-06-2025
- Dividend Yield
- COCH N/A
- LPCN N/A
- EPS Growth
- COCH N/A
- LPCN N/A
- EPS
- COCH N/A
- LPCN N/A
- Revenue
- COCH $278,000.00
- LPCN $7,922,926.00
- Revenue This Year
- COCH N/A
- LPCN N/A
- Revenue Next Year
- COCH $19.76
- LPCN N/A
- P/E Ratio
- COCH N/A
- LPCN N/A
- Revenue Growth
- COCH 15.35
- LPCN N/A
- 52 Week Low
- COCH $1.08
- LPCN $3.20
- 52 Week High
- COCH $11.46
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- COCH 38.92
- LPCN 38.51
- Support Level
- COCH $1.21
- LPCN $4.48
- Resistance Level
- COCH $1.50
- LPCN $4.89
- Average True Range (ATR)
- COCH 0.20
- LPCN 0.35
- MACD
- COCH 0.01
- LPCN -0.06
- Stochastic Oscillator
- COCH 32.26
- LPCN 9.60
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing innovative medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.